The GISSI Story (1983-1996): A comprehensive review

Journal of Interventional Cardiology

Volumn 10, Issue 1, 1997, Pages 3-28

  Tognoni, Gianni ^a   Fresco, Claudio ^b   Maggioni, Aldo P ^b   Turazza, Fabio M ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANISTREPLASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; HEPARIN; LISINOPRIL; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MORTALITY; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SMOKING; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0030945373     PISSN: 08964327     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8183.1997.tb00002.x     Document Type: Review

References (81)

1. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986;ii:57-66.
2. The I.S.A.M. Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). N Engl J Med 1986;314:1465-1471.
3. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;ii: 349-360.
4. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;ii: 397-402.
5. Tognoni G, Franzosi MG, Pampallona S. Trombolisi sistemica nell'infarto miocardico acuto: Anticipazioni sullo studio italiano. Cardiologia 1984, 18 Corso di Aggiornamento, Centro A. De Gasperis, Milano, pp. 261-267.
6. Farina ML, Franzosi MG, Pampallona S, et al. Fibrinolisi sistemica nell'infarto miocardico acuto. Casistica, metodo, risultati preliminari del GISSI. Cardiologia 1985, 19 Corso di Aggiornamento, Centro A. De Gasperis, Milano, pp. 290-297.
7. GISSI-2 Gruppo Italiano per lo Studio della Streptokinasi nell'Infarto Miocardico. A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. Lancet 1990; 336:65-71.
8. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-1122.
9. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications tor fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-322.
10. De Vita C, Franzosi MG, Geraci E, et al. GISSI-2: Mortality plus extensive left ventricular damage as "end-points." Lancet 1990;335:289.
11. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Long-term effects of intravenous thrombolysis in acute myocardial infarction: Final report of the GISSI study. Lancet 1987;ii:871-874.
12. International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990;336:71-75.
13. White HD. GISSI-2 and the heparin controversy. Lancet 1990; 336:297-298.
14. Sobel BE, Hirsh J. Principles and practice of coronary thrombolysis and conjunctive treatment. Am J Cardiol 1991;68: 382-388.
15. Ross AM, Hsia J, Hamilton W, et al. Heparin versus aspirin after recombinant tissue plasminogen activator therapy in myocardial infarction: A randomized trial. JACC 1990; 15(Suppl. A):64A.
16. Topol EJ, George BS, Kereiakes DJ, et al. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989;79:281-286.
17. Bleich SD, Nichols T, Schumacher R, et al. The role of heparin following coronary thrombolysis with tissue plasminogen activator (t-PA). Circulation 1989;80:II-113.
18. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
19. Multicenter Post-Infarction Research Group. Risk stratification after myocardial infarction. N Engl J Med 1983;309: 331-336.
20. Moss AJ, Bigger JT, Odoroff CL. Postinfarct risk stratification. Progr Cardiovasc Dis 1987;29:389-412.
21. While HD, Norris RM, Brown MA, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76: 44-51.
22. Oldroyd KG, Pye MP, Ray SG, et al. Effects of early captopril administration on infarct expansion, left ventricular remodeling and exercise capacity after acute myocardial infarction. Am J Cardiol 1991;68:713-718.
23. Sharpe N, Smith H, Murphy J, et al. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet 1991;337: 872-876.
24. Jugdutt BI, Warnica JJ. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Circulation 1988;78:906-919.
25. Eaton LW, Weiss JL, Bulkley BG, et al. Regional cardiac dilation after acute myocardial infarction. N Engl J Med 1979; 300:57-62.
26. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161-1172.
27. Pfeffer MA, Kamas GA, Vaughan DE, et al. Effect of captopril on progressive ventricular dilation after anterior myocardial infarction. N Engl J Med 1988;319:80-86.
28. Sharpe N, Murphy J, Smith H, et al. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1988;i:255-259.
29. Yusuf S, Collins R, MacMahon S, et al. Effect of intravenous nitrates on mortality in acute myocardial infarction: An overview of the randomised trials. Lancet 1988;i:1088-1092.
30. Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327:678-684.
31. GISSI-3 Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3 study protocol on the effects of lisinopril, of nitrates, and of their association in patients with acute myocardial infarction. Am J Cardiol 1992;70:62C-69C.
32. Volpi A, De Vita C, Franzosi MG, et al. Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis: Results of the GISSI-2 data base. Circulation 1993;88:416-429.
33. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828.
34. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
35. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
36. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327:669-677.
37. Latini R, Maggioni AP, Flather M, et al. ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation 1995;92:3132-3137.
38. ISIS Collaborative Group, Oxford, UK. ISIS-4: Randomised study of oral isosorbide mononitrate in over 50,000 patients with suspected acute myocardial infarction. Circulation 1993; 88:I-394.
39. Wilcox RG, von der Lippe G, Olsson CG, et al., for the ASSET Study Group. Trial of tissue plasminogen activator for mortality reduction in the acute myocardial infarction. Lancet 1988; ii:525-530.
40. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial. Lancet 1988;i:545-549.
41. ISIS-3 (Third International Study of Infarct Survival Collaborative Group). ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin and heparin vs heparin alone among 41299 cases of suspected acute myocardial infarction. Lancet 1992;339: 753-770.
42. Maggioni AP, Franzosi MG, Santoro E, et al., the GISSI-2, and the International Study Group. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. N Engl J Med 1992;327:1-6.
43. Maggioni AP, Franzosi MG, Farina ML, et al. Cerebrovascular events after myocardial infarction: Analysis of the GISSI trial. Br Med J 1991;302:1428-1431.
44. Simoons ML, Maggioni AP, Knatterud G, et al. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet 1993;342:1523-1528.
45. Maggioni AP, Maseri A, Fresco C, et al., on behalf of the Investigators of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2). Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis. N Engl J Med 1993;329: 1442-1448.
46. Volpi A, De Vita C, Franzosi MG, et al., and the Ad hoc working group of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-2 Data base. Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis. Results of the GISSI-2 data base. Circulation 1993;88:416-429.
47. Tofler GH, Stone PH, Muller JE, et al., and the MILIS study group. Effect of gender and race on prognosis after myocardial infarction: Adverse prognosis of women, particularly black women. JACC 1987;9:473-482.
48. Greeland P, Reicher-Reiss H, Godbourt U, et al., and the Israeli SPRINT investigator. In-hospital and 1-year mortality in 1,524 women after myocardial infarction: Comparison with 4,315 men. Circulation 1991;83:484-491.
49. Norris RM, Caughey DE, Deeming LW, et al. Coronary prognostic index for predicting survival after recovery from acute myocardial infarction. Lancet 1970;2:485-487.
50. Henning H, Gilpin EA, Covell JW, et al. Prognosis after acute myocardial infarction: A multivariate analysis of mortality and survival. Circulation 1979;59:1124-1136.
51. Henning R, Wedel H. The long-term prognosis after myocardial infarction: A five-year follow-up study. Eur Heart J 1981; 2:65-74.
52. Martin CA, Thompson PL, Armstrong BK, et al. Long-term prognosis after recovery from myocardial infarction: A nine-year follow-up of the Perth Coronary Register. Circulation 1983;68:961-969.
53. Weinblatt E, Shapiro S, Frank CW. Prognosis of women with newly diagnosed coronary heart disease: A comparison with course of disease among men. Am J Public Health 1973;63: 577-593.
54. Pohjola S, Siltanen P, Romo M. Five-year survival of 728 patients after myocardial infarction: A community study. Br Heart J 1980;43:176-183.
55. Wong ND, Cupples LA, Ostfeld AM, et al. Risk factors for long-term coronary prognosis after initial myocardial infarction: The Framingham Study. Am J Epidemiol 1989;130: 469-480.
56. Rivers JT, White JD, Cross DB, et al. Reinfarction after thrombolysis therapy for acute myocardial infarction followed by conservative management: Incidence and effect of smoking. JACC 1990;16:340-348.
57. Barbash GI, White HD, Modan M, et al. Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Circulation 1993;87:53-58.
58. Mueller HS, Cohen LS, Braunwald E, et al. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the thrombolysis in myocardial infarction (TIMI) trial, phase II. Circulation 1992;85:1254-1264.
59. Gomez MA, Karagounis LA, Allen A, et al. Effect of cigarette smoking on coronary patency after thrombolytic therapy for myocardial infarction. Am J Cardiol 1993;72:373-378.
60. Volpi A, Maggioni A, Franzosi MG, et al. In-hospital prognosis of patients with acute myocardial infarction complicated by primary ventricular fibrillation. N Engl J Med 1987;317: 257-261.
61. Volpi A, Cavalli A, Franzosi MG, et al., and the GISSI Investigators. One-year prognosis of primary ventricular fibrillation complicating acute myocardial infarction. Am J Cardiol 1989; 63:1174-1178.
62. Volpi A, Cavalli A, Santoro E, et al., and GISSI Investigators. Incidence and prognosis of secondary ventricular fibrillation in acute myocardial infarction. Evidence for a protective effect of Thrombolytic therapy. Circulation 1990;82:1279-1288.
63. The Coronary Drug Project Research Group. Prognostic importance of premature beats following myocardial infarction. Experience in the coronary drug project. JAMA 1973;223: 1116-1124.
64. Ruberman W, Weinblatt E, Goldberg JD, et al. Ventricular premature complexes and sudden death after myocardial infarction. Circulation 1981;64:297-305.
65. Bigger JT, Weld FM, Rolnitzky LM. Prevalence, characteristics and significance of ventricular tachycardia (three or more complexes) detected with ambulatory electrocardiographic recording in the late hospital phase of acute myocardial infarction. Am J Cardiol 1981;48:815-823.
66. Maggioni AP, Zuanetti G, Franzosi MG, et al., on behalf of GISSI-2 Investigators. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results. Circulation 1993;87: 312-322.
67. Toole JC, Silverman ME. Pericarditis of acute myocardial infarction. Chest 1975;67:647-653.
68. Galve E, Garcia-Del Castillo H, Evangelista A, et al. Pericardial effusion in the course of myocardial infarction: Incidence, natural history, and clinical relevance. Circulation 1986;73: 294-299.
69. Krainin FM, Flessas AP, Spodick DH. Infarction-associated pericarditis. N Engl J Med 1984;311:1211-1214.
70. Correale E, Maggioni AP, Romano S, et al., on behalf of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI). Comparison of frequency, diagnostic and prognostic significance of pericardial involvement in acute myocardial infarction treated with and without thrombolytics. Am J Cardiol 1993;71:1377-1381.
71. The Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: Final report of the Pooling Project. J Chron Dis 1978;31: 201-306.
72. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1: Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-774.
73. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic und diastolic, and cardiovascular risk. US population data. Arch Intern Med 1993;153:598-615.
74. Fresco C, Avanzini F, Bosi S, et al., on behalf of the GISSI-2 Investigators. Prognostic value of a history of hypertension in 11483 patients with acute myocardial infarction treated with thrombolysis. J Hypertens 1996;14:743-750.
75. Théroux P, Waters DD, Halphen C, et al. Prognostic value of exercise testing soon after myocardial infarction. N Engl J Med 1979;301:341-345.
76. Froelicher VF, Perdue S, Pewen W, et al. Application of metaanalysis using an electronic spread sheet to exercise testing in patients after myocardial infarction. Am J Med 1987;83: 1045-1054.
77. Villella A, Maggioni AP, Villella M, et al., on behalf of the GISSI-2 Investigators. Prognostic significance of maximal exercise testing after myocardial infarction treated with thrombolytic agents: The GISSI-2 data-base. Lancet 1995;346: 523-529.
78. Sanz G, Castaner A, Betriu A, et al. Determinants of prognosis in survivors of myocardial infarction. N Engl J Med 1982; 306:1065-1070.
79. Nicod P, Gilpin E, Dittrich H, et al. Influence on prognosis and morbidity of left ventricular ejection fraction with and without signs of left ventricular failure after acute myocardial infarction. Am J Cardiol 1988;61:1165-1171.
80. Gadsboll N, Hoilund-Carlsen PF, Madsen EB, et al. Right and left ventricular ejection fractions: Relation to one-year prognosis in acute myocardial infarction. Eur Heart J 1987;8: 1201-1209.
81. Serruys PW, Simoons ML, Suryapranata H, et al., for the Working Group on Thrombolytic Therapy in Acute Myocardial Infarction of The Netherlands Interuniversity Cardiology Institute. Preservation of global and regional left ventricular function after early thrombolysis in acute myocardial infarction. JACC 1986;7:729-742.